Epidemiology of Prostate Cancer in Saudi Arabia | Chapter 3 | New Frontiers in Medicine and Medical Research Vol. 14

Problem identification: Prostate cancer has become more common around the world in recent years as understanding and tools for early detection of cancer have improved. Prostate cancer is the second most frequent cancer in the Middle East, and it is the sixth highest cause of death among men. The purpose of this research is to determine the impact of genetics and environmental variables in the development and progression of prostate cancer in Middle Eastern countries, with a particular focus on the prevalence and mortality of prostate cancer in Saudi Arabia. The study will also look into potential risk factors for the development of prostate cancer in Migrants.

Literature search: An extensive literature search was conducted to locate papers and research on the prevalence of prostate cancer in Saudi Arabia, as well as possible reasons for its rising prevalence over time. The literature search also includes studies on the known and suspected risk factors that contribute to the development of prostate cancer.

Conclusion: The findings of the literature study and analysis in this paper revealed that Arab men's genetics and individual anatomy play a role in the development of prostate cancer. For environmental reasons, it was discovered that Arab men's changing lifestyles, as well as their increasing openness to Western influence, contributed to the high occurrence of prostate cancer. It was also discovered that as the level of medical practises in Saudi Arabia improves, more cases of prostate cancer are predicted to be recognised, as residents would have more access to early diagnosis of the disease.

Author (S) Details

Abdulghani A. Naeem
Department of Molecular & Clinical Cancer Medicine, Liverpool University, Liverpool, L69 3GA, United Kingdom.

Saud A. Abdulsamad
Department of Molecular & Clinical Cancer Medicine, Liverpool University, Liverpool, L69 3GA, United Kingdom.

Xi Jin
Institute of Urology, West China Hospital, Sichuan University, No.37 Guo Xue Xiang, Chengdu, Sichuan, 610041, China.

Gang He
Sichuan Antibiotics Industrial Institute, Chengdu University, Chengdu 610081, China.

Jiachen Zhang
Department of Molecular & Clinical Cancer Medicine, Liverpool University, Liverpool, L69 3GA, United Kingdom.

Qiang Wei
Institute of Urology, West China Hospital, Sichuan University, No.37 Guo Xue Xiang, Chengdu, Sichuan, 610041, China.

Youqiang Ke
Department of Molecular & Clinical Cancer Medicine, Liverpool University, Liverpool, L69 3GA, United Kingdom and Institute of Urology, West China Hospital, Sichuan University, No.37 Guo Xue Xiang, Chengdu, Sichuan, 610041, China.

View Book :- https://stm.bookpi.org/NFMMR-V14/article/view/3385